Albeit the characterization of drug encapsulation efficiency and release kinetics need to be implemented and possibly controlled overtime, our results confirm the superior cytotoxic effects of secreted doxorubicin-EVs on HER2-positive breast cancer cells compared to the free drug, as already observed in other cell types [50]. This evidence concerns the gene ERBB2 and breast carcinoma.